CHF welcomed the Review of Medicines and Medical Device Regulation and, while we did not support removing the required pre-approval of therapeutic goods advertisements, we are pleased to work with the Therapeutic Goods Administration (TGA) to ensure that new arrangements will continue to protect consumer interests. We applaud the efforts to streamline the management and encourage greater consistency in decision-making relating to complaints about the advertising of therapeutic goods to the public.